Orforglipron (Foundayo) Side Effects: What to Expect
Orforglipron, sold as Foundayo, is the first oral GLP-1 pill approved for weight loss in the US. Its side effects look much like injectable GLP-1 drugs: mostly gastrointestinal, mostly manageable, with a class boxed warning for thyroid tumors. Here is the full picture, with frequency data and practical management.
Orforglipron at a Glance
Eli Lilly received FDA approval for orforglipron (brand name Foundayo) on April 1, 2026, for chronic weight management in adults with obesity, or those who are overweight with at least one weight-related condition. It is a once-daily, small-molecule GLP-1 receptor agonist that can be taken any time of day without food or water restrictions, which sets it apart from oral semaglutide (Rybelsus).
Because it activates the same GLP-1 receptor as semaglutide and the GLP-1 arm of tirzepatide, orforglipron shares the class side effect pattern. The pill format does not remove these effects. If you have read our GLP-1 side effects guide, most of this will be familiar. For background on the drug itself, see our orforglipron overview and the Foundayo guide.
Common Side Effects
The adverse effects listed most often in the Foundayo labeling and clinical trials are gastrointestinal. They tend to peak during dose increases and settle as the body adapts.
- Nausea — the most frequently reported effect, usually mild to moderate
- Constipation — common; fiber, fluids, and movement help
- Diarrhea — common, often intermittent
- Vomiting — less common than nausea, more likely with rapid titration
- Indigestion and abdominal pain — bloating, reflux, and cramping
- Headache — reported in trials, often early in treatment
- Hair loss (alopecia) — typically linked to rapid weight loss rather than direct toxicity
These effects overlap heavily with semaglutide and tirzepatide. Our pages on managing GLP-1 nausea and constipation on GLP-1s apply directly here.
How Common Are These Effects?
In Lilly trials, gastrointestinal events were the dominant reason people reduced a dose or stopped treatment, mirroring the injectable GLP-1 experience. The pattern, rather than exact percentages, is what matters for most patients: GI effects are common but usually mild, and they decline over time.
| Side Effect | Relative Frequency | Typical Timing |
|---|---|---|
| Nausea | Most common | First days after a dose increase |
| Constipation / Diarrhea | Common | Throughout, often intermittent |
| Vomiting | Less common | With faster titration |
| Headache / Indigestion | Occasional | Early treatment |
| Hair loss | Occasional | Months in, with rapid weight loss |
The Thyroid Boxed Warning
Foundayo carries the GLP-1 class boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). In rodent studies, GLP-1 agonists caused thyroid C-cell tumors; whether this applies to humans is unknown. As a precaution, orforglipron is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Report symptoms such as a neck lump, hoarseness, trouble swallowing, or persistent shortness of breath to your prescriber. This warning is shared with semaglutide and tirzepatide; see our semaglutide and thyroid cancer explainer for the underlying evidence.
Serious but Less Common Risks
Beyond the thyroid warning, orforglipron shares several warnings with the GLP-1 class:
- Pancreatitis: Severe, persistent abdominal pain, sometimes radiating to the back. Stop the drug and seek care.
- Gallbladder disease: Rapid weight loss can trigger gallstones; watch for right upper abdominal pain, fever, or jaundice.
- Hypoglycemia: Low risk alone, higher when combined with insulin or sulfonylureas.
- Kidney injury: Dehydration from vomiting or diarrhea can stress the kidneys; stay hydrated.
- Diabetic retinopathy: Worth monitoring in people with diabetes and existing eye disease.
- Severe GI reactions: Persistent vomiting or signs of bowel obstruction need medical attention.
For a fuller class picture, see GLP-1 contraindications and who should not take a GLP-1.
Orforglipron vs Injectable GLP-1 Side Effects
A common assumption is that a pill is gentler than an injection. For orforglipron, that is not really the case. The side effects come from GLP-1 receptor activation, not from how the drug enters the body. In head-to-head terms, orforglipron looks similar to oral and injectable semaglutide on tolerability.
Where it does differ is convenience: no needles, and unlike Rybelsus, no requirement to take it on an empty stomach with a small sip of water and then wait. Compare options in which GLP-1 is best for weight loss, Foundayo vs Wegovy, and Foundayo vs Zepbound.
How to Manage Side Effects
Most people can stay on orforglipron by managing GI effects rather than stopping. Practical steps:
- Titrate slowly: The dose schedule exists to limit nausea. Do not rush increases.
- Eat smaller meals: Stop at the first sign of fullness; large meals worsen nausea.
- Lower the fat and sugar: Greasy and very sweet foods are common nausea triggers.
- Hydrate: Important if you have diarrhea or vomiting, both to feel better and to protect your kidneys.
- Manage constipation early: Fiber, fluids, and movement; a stool softener if needed.
- Protect your hair: Adequate protein, iron, and a steady (not crash) rate of weight loss reduce shedding.
If side effects make daily life hard, talk to your prescriber about holding the dose or slowing titration before quitting. Stopping suddenly often brings appetite back; our GLP-1 tapering guide covers a measured approach.
When to Contact a Doctor
Seek prompt medical attention for any of the following:
- Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis)
- Signs of a thyroid tumor: a neck lump, hoarseness, or trouble swallowing
- Right upper abdominal pain with fever or yellowing of the skin or eyes (possible gallbladder problem)
- Symptoms of severe dehydration or reduced urination
- Persistent vomiting or inability to keep fluids down
- Signs of a serious allergic reaction such as swelling or trouble breathing
Bottom Line
Orforglipron is a meaningful step because it delivers GLP-1 weight loss in a flexible daily pill. The trade-off is that it carries the same side effect profile as the rest of the class: mostly gastrointestinal, mostly manageable with slow titration, plus the standard thyroid boxed warning. For most people the effects ease within a few weeks. Knowing the warning signs, and when to call a clinician, is what separates a rough start from a dangerous one.
This guide is for education only and is not medical advice. Orforglipron is a prescription medication; discuss benefits and risks with a licensed clinician before starting, stopping, or changing treatment.
Related Guides
Frequently Asked Questions About Orforglipron
The most common side effects are gastrointestinal: nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain. These match the broader GLP-1 class. Most are mild to moderate, appear during dose increases, and fade as the body adapts. Headache and hair loss are also listed in the Foundayo label.
Yes. Like other GLP-1 receptor agonists, Foundayo (orforglipron) carries a boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It should not be used by anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The warning is based on rodent studies; human relevance is unconfirmed.
Not meaningfully. Because orforglipron is a once-daily pill, some people assume it is gentler, but its side effect profile in trials closely tracks injectable semaglutide and tirzepatide. The GI effects come from GLP-1 receptor activity, not the delivery route. A slow dose titration is still the main tool for tolerability.
Hair loss (alopecia) is listed among the adverse effects in the Foundayo label. As with semaglutide and tirzepatide, this is generally telogen effluvium, a temporary shedding triggered by rapid weight loss rather than a direct drug toxicity. It usually reverses once weight stabilizes and adequate protein and iron intake are maintained.
Most GI side effects are worst in the first few days after starting or increasing a dose, then improve over one to two weeks as tolerance develops. If nausea or diarrhea persists beyond a few weeks at a stable dose, that is worth raising with your prescriber, who may slow the titration or hold the dose.
People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take it. It is also not recommended in people with a history of pancreatitis, severe gastrointestinal disease such as gastroparesis, or during pregnancy. Discuss any history of gallbladder disease or diabetic retinopathy with your prescriber first.
Pancreatitis is a recognized risk across the GLP-1 class and is listed as a warning for orforglipron. It is uncommon. Severe, persistent abdominal pain that may radiate to the back, with or without vomiting, warrants stopping the drug and seeking medical care promptly.
Eat smaller, lower-fat meals, stop eating at the first sign of fullness, stay hydrated, and avoid greasy or very sweet foods. Because orforglipron has no food or water timing restrictions, you have flexibility in when you dose. If nausea is severe, ask your prescriber about a slower titration before considering anti-nausea medication.